NAD+
Nicotinamide Adenine Dinucleotide
NAD+ sits closer to mainstream integrative medicine and remains generally available through clinics that offer longevity-focused compounded therapies.
Current status
Legal
Cellular-energy interest, with current federal compounding constraints still in play.
FDA category
USP Monograph
Can pharmacies compound this?
Yes
Reclassification expected?
Unclear
Availability can still vary by pharmacy, but it is materially easier to source than restricted peptides.
Primary Use
Cellular-energy interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Jul 1, 2025
Ingredient remained available through approved or established compounding pathways.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when NAD+ status changes
State-specific notes
Tennessee
Commonly available through longevity clinics.